Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2005

Open Access 01-12-2005 | Review

A quest for therapeutic antigens in bone and soft tissue sarcoma

Authors: Satoshi Kawaguchi, Takuro Wada, Tomohide Tsukahara, Kazunori Ida, Toshihiko Torigoe, Noriyuki Sato, Toshihiko Yamashita

Published in: Journal of Translational Medicine | Issue 1/2005

Login to get access

Abstract

Over the past three decades, there have been remarkable advances in the treatment of bone and soft tissue sarcomas. These include the introduction of adjuvant chemotherapy, establishment of guidelines for adequate surgical margins, and the development of post-excision reconstruction. There have also been advances in the field of immunotherapy against bone and soft tissue sarcomas, which, unfortunately, have received less attention. However, lack of progress in chemotherapy-based treatments for bone and soft tissue sarcomas has reignited interest in immunotherapeutic approaches. Here we summarize current progress in the immunotherapy of bone and soft tissue sarcomas including the strategies utilized to identify tumor-associated antigens, and the design of clinical trials.
Appendix
Available only for authorised users
Literature
1.
Fletcher CDM, Rydholm A, Singer S, Sundaram M, Coindre JM: Soft tissue tumorus: Epidemiology, clinical features, histopathological typing and grading. Pathology and genetics of tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon: IARC Press, 12-18.
2.
Dorfman HD, Czerniak B, Kotz R, Vanel D, Park YK, Unni KK: WHO classification of tumours of bone: Introduction. Pathology and genetics of tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon: IARC Press, 227-232.
3.
Arndt CA, Crist WM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999, 341: 342-352. 10.1056/NEJM199907293410507.CrossRefPubMed
4.
Campbell CJ, Cohen J, Enneking WF: New therapies for osteogenic sarcoma. J Bone Joint Surg Am. 1975, 57: 143-144.PubMed
5.
Marcove RC, Mike V, Huvos AG, Southam CM, Levin AG: Vaccine trials for osteogenic sarcoma. A preliminary report. CA Cancer J Clin. 1973, 23: 74-80.CrossRefPubMed
6.
Marcove RC: A clinical trial of autogenous vaccines in the treatment of osteogenic sarcoma. Beitr Pathol. 1974, 153: 65-72.CrossRefPubMed
7.
Marsh B, Flynn L, Enneking WF: Immunologic aspects of osteosarcoma and their appication to therapy. J Bone Joint Surg Am. 1972, 54: 1367-1397.PubMed
8.
Neff JR, Enneking WF: Adoptive immunotherapy in primary osteosarcoma. An interim report. J Bone Joint Surg Am. 1975, 57: 145-148.PubMed
9.
Jaffe N, Frei E, Traggis D, Bishop Y: Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974, 291: 994-997.CrossRefPubMed
10.
Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ, Murphy ML: High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer. 1974, 33: 1151-1163.CrossRefPubMed
11.
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991, 254: 1643-1647.CrossRefPubMed
12.
Nabeta Y, Kawaguchi S, Sato Y, Wada T, Yamashita T, Sato N: Identification strategy and cataloguing of antigenic cancer epitopes. Mod Asp Immunobiol. 2000, 1: 17-19.
13.
Linehan DC, Bowne WB, Lewis JJ: Immunotherapeutic approaches to sarcoma. Semin Surg Oncol. 1999, 17: 72-77. 10.1002/(SICI)1098-2388(199907/08)17:1<72::AID-SSU9>3.0.CO;2-A.CrossRefPubMed
14.
Mackall CL, Berzofsky JA, Helman LJ: Targeting tumor specific translocation in sarcomas in pediatric patients for immunotherapy. Clin Orthop. 2000, 373: 25-31. 10.1097/00003086-200004000-00005.CrossRefPubMed
15.
Maki RG: Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol. 2001, 13: 270-274. 10.1097/00001622-200107000-00010.CrossRefPubMed
16.
Nabeta Y, Kawaguchi S, Sahara H, Ikeda H, Hirohashi Y, Goroku T, Sato Y, Tsukahara T, Torigoe T, Wada T, Kaya M, Hiraga H, Isu K, Yamawaki S, Ishii S, Yamashita T, Sato N: Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci. 2003, 8: 554-559. 10.1007/s00776-003-0663-5.CrossRefPubMed
17.
Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N: Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res. 2004, 64: 5442-5448.CrossRefPubMed
18.
Coffin CM, Fletcher CDM: Inflammatory myofibroblastic tumour. Pathology and genetics of tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon: IARC Press, 91-93.
19.
Coindre JM: Inflammatory malignant fibrous histiocytoma / Undifferentiated pleomorphic sarcoma with prominent inflammation. Pathology and genetics of tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon: IARC Press, 125-126.
20.
Melhem MF, Meisler AI, Saito R, Finley GG, Hockman HR, Koski RA: Cytokines in inflammatory malignant fibrous histiocytoma presenting with leukemoid reaction. Blood. 1993, 82: 2038-2044.PubMed
21.
Schiltz PM, Beutel LD, Nayak SK, Dillman RO: Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunol. 1997, 20: 377-386.
22.
Zietz C, Rumpler U, Sturzl M, Lohrs U: Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack. Am J pathol. 2001, 159: 963-970.PubMedCentralCrossRefPubMed
23.
Orui H, Ishikawa A, Okada K, Nishida J, Mitsui H, Kashiwa H, Tsuchiya T, Ogino T, Yamakawa M: Dendritic cell and effector cell infiltration in soft tissue sarcomas with reactive lymphoid hyperplasia. J Orthop Sci. 2003, 8: 669-677. 10.1007/s00776-003-0692-0.CrossRefPubMed
24.
Ogihara Y, Takeda K, Yanagawa T, Hirasawa Y: Spontaneous regression of lung metastases from osteosarcoma. Cancer. 1994, 74: 2798-2803.CrossRefPubMed
25.
Sabate JM, Llauger J, Torrubia S, Amores S, Franquet T: Osteosarcoma of the abdominal wall with spontaneous regression of lung metastases. AJR Am J Roentgenol. 1998, 171: 691-692.CrossRefPubMed
26.
Ichino Y, Ishikawa T: Cytolysis of autologous fresh osteosarcoma cells by human cytotoxic T lymphocytes propagated with T cell growth factor. Gann. 1983, 74: 584-594.PubMed
27.
Slovin SF, Lackman RD, Ferrone S, Kiely PE, Mastrangelo MJ: Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol. 1986, 137: 3042-3048.PubMed
28.
Tsukahara T, Kawaguchi S, Ida K, Kimura S, Tamura Y, Ikeda T, Torigoe T, Nagoya S, Wada T, Sato N, Yamashita T: HLA-restricted specific tumor cytolysis by autologous T cell cells infiltrating metastatic bone malignant fibrous histiocytoma of lymph node. J Orthop Res.
29.
Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK, June CH, Mackall CL: Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther. 2003, 2: 579-586.CrossRefPubMed
30.
Hayakawa M, Kawaguchi S, Ishii S, Murakami M, Uede T: B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells. Int J Cancer. 1997, 71: 1091-1102. 10.1002/(SICI)1097-0215(19970611)71:6<1091::AID-IJC28>3.0.CO;2-F.CrossRefPubMed
31.
Nagamori M, Kawaguchi S, Murakami M, Wada T, Inobe M, Ishii S, Uede T: In vivo immunogenicity of osteosarcoma cells that express B7-1a, an alternatively spliced form of B7-1. Anticancer Res. 2002, 22: 2009-2013.PubMed
32.
Nagamori M, Kawaguchi S, Murakami M, Wada T, Nagoya S, Yamashita T, Inobe M, Uede T: Intrinsic and extrinsic manipulation of B7/CTLA-4 interaction for induction of anti-tumor immunity against osteosarcoma cells. Anticancer Res. 2002, 22: 3223-3227.PubMed
33.
Tsuji H, Kawaguchi S, Wada T, Nagoya S, Inobe M, Yamashita T, Ishii S, Uede T: Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma. Cancer Gene Ther. 2002, 9: 747-755. 10.1038/sj.cgt.7700491.CrossRefPubMed
34.
Tsuji H, Kawaguchi S, Wada T, Nagoya S, Inobe M, Yagita H, Okumura K, Yamashita T, Uede T: Concurrent induction of T-cell activation and apoptosis of osteosarcoma cells by adenovirus-mediated B7-1/Fas chimeric gene transfer. Cancer Gene Ther. 2003, 10: 717-725. 10.1038/sj.cgt.7700624.CrossRefPubMed
35.
Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003, 100: 8372-8377. 10.1073/pnas.1533209100.PubMedCentralCrossRefPubMed
36.
Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005, 23: 741-750. 10.1200/JCO.2005.01.128.CrossRefPubMed
37.
Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996, 274: 94-96. 10.1126/science.274.5284.94.CrossRefPubMed
38.
Sato Y, Nabeta Y, Tsukahara T, Hirohashi Y, Syunsui R, Maeda A, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Wada T, Yamashita T, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Umeda T, Ishii S, Kawaguchi S, Sato N: Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol. 2002, 169: 1611-1618.CrossRefPubMed
39.
Sato Y, Sahara H, Tsukahara T, Kondo M, Hirohashi Y, Nabeta Y, Kawaguchi S, Ikeda H, Torigoe T, Ichimiya S, Tamura Y, Wada T, Yamashita T, Goto M, Takasu H, Sato N: Improved generation of HLA class I/peptide tetramers. J Immunol Methods. 2002, 271: 177-184. 10.1016/S0022-1759(02)00329-0.CrossRefPubMed
40.
Ida K, Kawaguchi S, Sato Y, Tsukahara T, Nabeta Y, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Kamiguchi K, Wada T, Nagoya S, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Ozaki T, Yoshikawa H, Yamashita T, Sato N: Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol. 2004, 173: 1436-1443.CrossRefPubMed
41.
Bennicelli JL, Barr FG: Chromosomal translocations and sarcomas. Curr Opin Oncol. 2002, 14: 412-419. 10.1097/00001622-200207000-00008.CrossRefPubMed
42.
Caligiuri MA, Verardi A, Scheinberg DA, Borrelo IM: Immunotherapeutic approaches for hematologic malignancies. Hematology. 2004, 337-353. 10.1182/asheducation-2004.1.337.
43.
Novellino L, Castelli C, Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother. 2005, 54: 187-207. 10.1007/s00262-004-0560-6.CrossRefPubMed
44.
Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H: Definition of specific peptide motifs for four major HLA-A alleles. J Immunol. 1994, 152: 3913-3924.PubMed
45.
Kondo A, Sidney J, Southwood S, del Guercio MF, Appella E, Sakamoto H, Celis E, Grey HM, Chesnut RW, Kubo RT: Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol. 1995, 155: 4307-4312.PubMed
46.
Nencioni A, Grunebach F, Patrone F, Brossart P: Anticancer vaccination strategies. Ann Oncol. 2004, 15: iv153-iv160. 10.1093/annonc/mdh920.PubMed
47.
Singh-Jasuja H, Emmerich NP, Rammensee HG: The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother. 2004, 53: 187-195. 10.1007/s00262-003-0480-x.CrossRefPubMed
48.
Worley BS, van den Broeke LT, Goletz TJ, Pendelton D, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenecity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001, 61: 6868-6875.PubMed
49.
Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 2002, 38: 158-164. 10.1002/mpo.1303.CrossRefPubMed
50.
Boeckle S, Pfister H, Steger G: A new cellular factor recognizes E2 binding sites of papillomaviruses which mediate transcriptional repression by E2. Virology. 2002, 293: 103-117. 10.1006/viro.2001.1231.CrossRefPubMed
51.
Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K: Expression of MAGE genes in osteosarcoma. J Orthop Res. 1997, 15: 128-132. 10.1002/jor.1100150119.CrossRefPubMed
52.
Naka N, Araki N, Nakanishi H, Itoh K, Mano M, Ishiguro S, de Bruijn DR, Myoui A, Ueda T, Yoshikawa H: Expression of SSX genes in human osteosarcomas. Int J Cancer. 2002, 98: 640-642. 10.1002/ijc.10277.CrossRefPubMed
53.
Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Valmori D: The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun. 2004, 4: 7-PubMed
54.
Segal NH, Blachere NE, Guevara-Patino JA, Gallardo HF, Shiu HYA, Viale A, Antonescu CR, Wolchok JD, Houghton AN: Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun. 2005, 5: 2-PubMed
55.
Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T: MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer. 1996, 69: 375-380. 10.1002/(SICI)1097-0215(19961021)69:5<375::AID-IJC4>3.0.CO;2-2.CrossRefPubMed
56.
Ueda T, Oji Y, Naka N, Nakano Y, Takahashi E, Koga S, Asada M, Ikeba A, Nakatsuka S, Abeno S, Hosen N, Tomita Y, Aozasa K, Tamai N, Myoui A, Yoshikawa H, Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci. 2003, 94: 271-276.CrossRefPubMed
57.
Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995, 92: 11810-11813.PubMedCentralCrossRefPubMed
58.
Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ, Scanlan MJ: Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A. 2003, 100: 2651-2656. 10.1073/pnas.0437972100.PubMedCentralCrossRefPubMed
59.
Sega NH, Blachere NE, Shiu HYA, Leejee S, Antonescu CR, Lewis JJ, Wolchok JD, Houghton AN: Antigens recognized by autologous antibodies of patients with soft tissue sarcoma. Cancer Immun. 2005, 5: 4-
60.
Dillman R, Barth N, Selvan S, Beutel L, de Leon C, DePriest C, Peterson C, Nayak S: Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 2004, 19: 581-588.CrossRefPubMed
61.
Kawaguchi S, Wada T, Ida K, Sato Y, Nagoya S, Tsukahara T, Kimura S, Sahara H, Ikeda H, Shimozawa K, Asanuma H, Torigoe T, Hiraga H, Ishii T, Tatezaki SI, Sato N, Yamashita T: Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med. 2005, 3: 1-10.1186/1479-5876-3-1.PubMedCentralCrossRefPubMed
62.
Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J: Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet. 2000, 356: 1163-1165. 10.1016/S0140-6736(00)02762-8.CrossRefPubMed
63.
Matsuzaki A, Suminoe A, Hattori H, Hoshina T, Hara T: Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol. 2002, 24: 220-223. 10.1097/00043426-200203000-00012.CrossRefPubMed
64.
Friedman MA, Carter SK: The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 1972, 4: 482-510.CrossRefPubMed
65.
Kaya M, Wada T, Nagoya S, Kawaguchi S, Isu K, Yamashita T: Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. J Bone Joint Surg Br. 2004, 86: 143-147.PubMed
66.
Burchnal JH: A giant step forward – If... N Engl J Med. 1974, 291: 1029-1031.CrossRef
Metadata
Title
A quest for therapeutic antigens in bone and soft tissue sarcoma
Authors
Satoshi Kawaguchi
Takuro Wada
Tomohide Tsukahara
Kazunori Ida
Toshihiko Torigoe
Noriyuki Sato
Toshihiko Yamashita
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2005
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-3-31

Other articles of this Issue 1/2005

Journal of Translational Medicine 1/2005 Go to the issue

Commentary

Gene expression profiling of melanoma cells – searching the haystack

Research

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms

Review

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

Research

The subcellular distribution of myeloid-related protein 8 (MRP8) and MRP14 in human neutrophils

Research

T lymphocytes among HIV-infected and -uninfected infants: CD4/CD8 ratio as a potential tool in diagnosis of infection in infants under the age of 2 years

Research

The antitumor immune response in HER-2 positive, metastatic breast cancer patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits